Digital health is a term that refers to the use of digital technologies to improve health and healthcare. This includes a wide range of applications, such as electronic health records, telemedicine, health monitoring devices, and health-related apps and software. Digital health technologies can be used to improve the efficiency, effectiveness, and accessibility of healthcare, and to enable individuals to manage their own health and wellbeing more effectively. Digital health is an increasingly important area of healthcare, as it offers the potential to improve health outcomes and reduce costs. What is a digital health MVP?

Abstract--This article reviews the landscape of ethical challenges of integrating artificial intelligence (AI) into smart healthcare products, including medical electronic devices. Differences between traditional ethics in the medical domain and emerging ethical challenges with AI-driven healthcare are presented, particularly as they relate to transparency, bias, privacy, safety, responsibility, justice, and autonomy. Open challenges and recommendations are outlined to enable the integration of ethical principles into the design, validation, clinical trials, deployment, monitoring, repair, and retirement of AI-based smart healthcare products. Healthcare systems in countries around the been approved by the FDA, and there are many more globe are struggling to cope with health emergencies in the development pipeline [8]. Many direct to such as the COVID-19 pandemic, provide universal consumer AI devices for health monitoring and wellbeing health coverage, and improve general health and wellbeing.

Artificial intelligence (AI) in healthcare is a potentially revolutionary tool to achieve improved healthcare outcomes while reducing overall health costs. While many exploratory results hit the headlines in recent years there are only few certified and even fewer clinically validated products available in the clinical setting. This is a clear indication of failing translation due to shortcomings of the current approach to AI in healthcare. In this work, we highlight the major areas, where we observe current challenges for translation in AI in healthcare, namely precision medicine, reproducible science, data issues and algorithms, causality, and product development. For each field, we outline possible solutions for these challenges. Our work will lead to improved translation of AI in healthcare products into the clinical setting

The tech industry of India has been a reliable partner to most of the world's top organisations in providing software and digital solutions, making them more competitive. The tech giant, Bosch, is one of the earliest European companies to do business in India. RBEI (Robert Bosch Engineering and Business Solutions) is one of the largest R&D centres in India. Most of the products which Bosch produces -- from automotive components to washing machines -- have SW and engineering contributions from RBEI. Currently, all of Bosch's business, including automotive components, building technology, industrial technology and consumer goods are in India with local manufacturing.

In a constantly changing world where virtual and physical environments are converging, ever-evolving digital technologies continue to disrupt the medical device industry. Besides, an uncertain environment, resulting from the ongoing COVID-19 outbreak has forced healthcare device manufacturers to adopt advanced technologies and tap into enormously growing medical device markets. At the same time, the increased connectivity between medical devices, physicians and consumers is necessitating OEMs to design and develop technologically advanced medical solutions. The digitization of manufacturing is, thus considered to be one of the core adjustments for healthcare manufacturers and OEMs to provide better patient care and remain competitive in the medical device markets. Advanced technologies like IoT, AI/ML, cloud, RPA, augmented and virtual reality hold a great potential to revolutionize the medical device manufacturing processes.

Artificial Intelligence (AI) in healthcare holds great potential to expand access to high-quality medical care, whilst reducing overall systemic costs. Despite hitting the headlines regularly and many publications of proofs-of-concept, certified products are failing to breakthrough to the clinic. AI in healthcare is a multi-party process with deep knowledge required in multiple individual domains. The lack of understanding of the specific challenges in the domain is, therefore, the major contributor to the failure to deliver on the big promises. Thus, we present a decision perspective framework, for the development of AI-driven biomedical products, from conception to market launch. Our framework highlights the risks, objectives and key results which are typically required to proceed through a three-phase process to the market launch of a validated medical AI product. We focus on issues related to Clinical validation, Regulatory affairs, Data strategy and Algorithmic development. The development process we propose for AI in healthcare software strongly diverges from modern consumer software development processes. We highlight the key time points to guide founders, investors and key stakeholders throughout their relevant part of the process. Our framework should be seen as a template for innovation frameworks, which can be used to coordinate team communications and responsibilities towards a reasonable product development roadmap, thus unlocking the potential of AI in medicine.

Sign in to report inappropriate content. Afiniti's use of artificial intelligence in the healthcare industry encourages preventative care, increasing the likelihood that people take advantage of opportunities in the present to preclude more serious issues down the road.

Sign in to report inappropriate content. Afiniti's use of artificial intelligence in the healthcare industry encourages preventative care, increasing the likelihood that people take advantage of opportunities in the present to preclude more serious issues down the road.

Approvals for AI-based healthcare products are streaming in from regulators around the globe, with medical imaging leading the way. It's just the start of what's expected to become a steady flow as submissions rise and the technology becomes better understood. More than 90 medical imaging products using AI are now cleared for clinical use, thanks to approvals from at least one global regulator, according to Signify Research Ltd., a U.K. consulting firm in healthcare technology. Regulators in Europe and the U.S. are leading the pace. Each has issued about 60 approvals to date.

Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 that can generally be identified by words such as "to transform," "multiyear," "commitment," "to found," "aims," "vision," "potential," "can," "will," "plan," "expect," "anticipate," "committed," or similar terms, or regarding the development or adoption of potentially transformational technologies and business models and the collaboration with Microsoft; or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the healthcare products described in this press release, or regarding potential future revenues from collaboration with Microsoft or such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the collaboration with Microsoft will achieve any or all of its intended goals or objectives, or in any particular time frame.